A328130 Stock Overview
Develops and provides AI based software solutions for cancer screening/diagnosis and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lunit Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩55,000.00 |
| 52 Week High | ₩139,750.00 |
| 52 Week Low | ₩46,400.00 |
| Beta | 0 |
| 1 Month Change | -3.17% |
| 3 Month Change | -9.54% |
| 1 Year Change | 13.17% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 175.00% |
Recent News & Updates
Shareholder Returns
| A328130 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | -3.3% | -0.8% | -1.7% |
| 1Y | 13.2% | -5.5% | 0.6% |
Return vs Industry: A328130 exceeded the KR Healthcare Services industry which returned -5.5% over the past year.
Return vs Market: A328130 exceeded the KR Market which returned 0.6% over the past year.
Price Volatility
| A328130 volatility | |
|---|---|
| A328130 Average Weekly Movement | 6.3% |
| Healthcare Services Industry Average Movement | 5.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.3% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A328130 has not had significant price volatility in the past 3 months.
Volatility Over Time: A328130's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 259 | Beomseok Brandon Suh | www.lunit.io |
Lunit Inc. develops and provides AI based software solutions for cancer screening/diagnosis and treatment. It offers AI solution for chest X-ray and mammography, as well as AI-powered biomarker for immune phenotyping and PD-L1 quantification for immunotherapy. The company was incorporated in 2013 and is based in Seoul, South Korea.
Lunit Inc. Fundamentals Summary
| A328130 fundamental statistics | |
|---|---|
| Market cap | ₩1.59t |
| Earnings (TTM) | -₩46.02b |
| Revenue (TTM) | ₩19.25b |
82.4x
P/S Ratio-34.5x
P/E RatioIs A328130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A328130 income statement (TTM) | |
|---|---|
| Revenue | ₩19.25b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩19.25b |
| Other Expenses | ₩65.27b |
| Earnings | -₩46.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60k |
| Gross Margin | 100.00% |
| Net Profit Margin | -239.09% |
| Debt/Equity Ratio | 0% |
How did A328130 perform over the long term?
See historical performance and comparison